• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Opinion

Video

FDA Approved Treatments: Topical Ruxolitinib and Vitiligo Management

Author(s):

Andrea Rosik, PA-C

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!
Related Videos
Related Content
Recap: 2025 Revolutionizing Atopic Dermatitis Conference
June 17th 2025

Recap: 2025 Revolutionizing Atopic Dermatitis Conference

Derm Dispatch: A Comprehensive Guide to Managing Eczema with Integrative Medicine
March 31st 2025

Derm Dispatch: A Comprehensive Guide to Managing Eczema with Integrative Medicine

Q&A: Peter Lio, MD, on Safety in Pediatric AD Management and the Promise of Precision Medicine
June 16th 2025

Q&A: Peter Lio, MD, on Safety in Pediatric AD Management and the Promise of Precision Medicine

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
August 2nd 2024

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

Looking Ahead to Povorcitininb for HS and the Availability of Generic Tofacitinib
June 13th 2025

Looking Ahead to Povorcitininb for HS and the Availability of Generic Tofacitinib

A Clinician’s Perspective of RAD 2025: Part 1
June 12th 2025

A Clinician’s Perspective of RAD 2025: Part 1

© 2025 MJH Life Sciences

All rights reserved.